Xiang‐Nan Yu

1.3k total citations
39 papers, 988 citations indexed

About

Xiang‐Nan Yu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Xiang‐Nan Yu has authored 39 papers receiving a total of 988 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 11 papers in Cancer Research and 6 papers in Oncology. Recurrent topics in Xiang‐Nan Yu's work include RNA modifications and cancer (7 papers), MicroRNA in disease regulation (6 papers) and Cancer-related molecular mechanisms research (5 papers). Xiang‐Nan Yu is often cited by papers focused on RNA modifications and cancer (7 papers), MicroRNA in disease regulation (6 papers) and Cancer-related molecular mechanisms research (5 papers). Xiang‐Nan Yu collaborates with scholars based in China, Canada and Cyprus. Xiang‐Nan Yu's co-authors include Ji‐Min Zhu, Xianglin Zhou, Mina Zhang, Xizhong Shen, Jinghao Li, Taotao Liu, Ling Dong, Xuemei Jiang, Shu‐Qiang Weng and Guangcong Zhang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Stroke.

In The Last Decade

Xiang‐Nan Yu

38 papers receiving 982 citations

Peers

Xiang‐Nan Yu

PRM

Chaojie Liang China

Feng Jin China

Erhui Jiang China

Xiaohui Shen China

Yilong Wang China

Atul Ranjan India

Xiangfu Chen China

Zhenguo Sun China

Hang Yuan China

Xiong Lei China

Chaojie Liang China

Xiang‐Nan Yu

316 ×0.6

266 ×0.7

209 ×1.2

72 ×0.5

PRM

168 ×1.1

Citations per year, relative to Xiang‐Nan Yu Xiang‐Nan Yu (= 1×) peers Chaojie Liang

Countries citing papers authored by Xiang‐Nan Yu

Since Specialization

Citations

This map shows the geographic impact of Xiang‐Nan Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiang‐Nan Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiang‐Nan Yu more than expected).

Fields of papers citing papers by Xiang‐Nan Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiang‐Nan Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiang‐Nan Yu. The network helps show where Xiang‐Nan Yu may publish in the future.

Co-authorship network of co-authors of Xiang‐Nan Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiang‐Nan Yu. A scholar is included among the top collaborators of Xiang‐Nan Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiang‐Nan Yu. Xiang‐Nan Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Guangcong, Kang Song, Jun Du, et al.. (2024). Bismuth-based mesoporous nanoball carrying sorafenib for synergistic photothermal and molecularly-targeted therapy in an orthotopic hepatocellular carcinoma xenograft mouse model. Colloids and Surfaces B Biointerfaces. 245. 114279–114279. 2 indexed citations

Yu, Xiang‐Nan, et al.. (2024). Single-Point Incremental Forming (SPIF) of AA5754 Aluminium Alloy Blanks: Experimental and numerical studies. SHILAP Revista de lepidopterología. 401. 1005–1005.

Zhang, Guangcong, Xiang‐Nan Yu, Hongying Guo, et al.. (2023). PRP19 Enhances Esophageal Squamous Cell Carcinoma Progression by Reprogramming SREBF1-Dependent Fatty Acid Metabolism. Cancer Research. 83(4). 521–537. 20 indexed citations

Zhang, Guangcong, Ning‐Ping Zhang, Hai‐Ning Liu, et al.. (2022). microRNA-106b-5p Promotes Cell Growth and Sensitizes Chemosensitivity to Sorafenib by Targeting the BTG3/Bcl-xL/p27 Signaling Pathway in Hepatocellular Carcinoma. Journal of Oncology. 2022. 1–15. 9 indexed citations

Sun, Jialei, Ning‐Ping Zhang, Guangcong Zhang, et al.. (2021). Tumor cell-imposed iron restriction drives immunosuppressive polarization of tumor-associated macrophages. Journal of Translational Medicine. 19(1). 347–347. 36 indexed citations

Liu, Yueyang, Xiaohang Che, Haotian Zhang, et al.. (2021). CAPN1 (Calpain1)-Mediated Impairment of Autophagic Flux Contributes to Cerebral Ischemia-Induced Neuronal Damage. Stroke. 52(5). 1809–1821. 27 indexed citations

Wu, Hong-Fen, et al.. (2021). Upregulation of Nei-Like DNA Glycosylase 3 Predicts Poor Prognosis in Hepatocellular Carcinoma. Journal of Oncology. 2021. 1–11. 8 indexed citations

Yu, Xiang‐Nan, Guangcong Zhang, Hai‐Ning Liu, et al.. (2021). Pre-mRNA processing factor 19 functions in DNA damage repair and radioresistance by modulating cyclin D1 in hepatocellular carcinoma. Molecular Therapy — Nucleic Acids. 27. 390–403. 9 indexed citations

Shi, Xuan, Taotao Liu, Xiang‐Nan Yu, et al.. (2020). microRNA-93-5p promotes hepatocellular carcinoma progression via a microRNA-93-5p/MAP3K2/c-Jun positive feedback circuit. Oncogene. 39(35). 5768–5781. 41 indexed citations

10.

Yu, Xiang‐Nan, et al.. (2020). Upregulation of Excision Repair Cross-Complementation Group 6-Like (ERCC6L) Promotes Tumor Growth in Hepatocellular Carcinoma. Digestive Diseases and Sciences. 66(4). 1097–1109. 10 indexed citations

11.

Yu, Xiang‐Nan, Guangcong Zhang, Jialei Sun, et al.. (2020). Enhanced mLST8 Expression Correlates with Tumor Progression in Hepatocellular Carcinoma. Annals of Surgical Oncology. 27(5). 1546–1557. 11 indexed citations

12.

Yu, Xiang‐Nan, Yong Deng, Guangcong Zhang, et al.. (2020). Sorafenib-Conjugated Zinc Phthalocyanine Based Nanocapsule for Trimodal Therapy in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model. ACS Applied Materials & Interfaces. 12(15). 17193–17206. 37 indexed citations

13.

Liu, Li‐Li, Ji‐Min Zhu, Xiang‐Nan Yu, et al.. (2019). <p>UBE2T promotes proliferation via G2/M checkpoint in hepatocellular carcinoma</p>. Cancer Management and Research. Volume 11. 8359–8370. 33 indexed citations

14.

Yu, Xiang‐Nan, Hongying Guo, Taotao Liu, et al.. (2019). Upregulated calcium‐binding tyrosine phosphorylation‐regulated protein‐a/b regulates cell proliferation and apoptosis and predicts poor prognosis in hepatocellular carcinoma. Journal of Cellular Biochemistry. 121(4). 2938–2949. 6 indexed citations

15.

Chen, Hong, Hairong Zhu, Xiang‐Nan Yu, et al.. (2019). <p>Overexpressed pepsinogen C is associated with poor prognosis in human hepatocellular carcinoma: a tissue microarray study</p>. Cancer Management and Research. Volume 11. 2927–2934. 5 indexed citations

16.

Li, Rong, Xuemei Jiang, Yingai Zhang, et al.. (2019). Cyclin B2 Overexpression in Human Hepatocellular Carcinoma is Associated with Poor Prognosis. Archives of Medical Research. 50(1). 10–17. 66 indexed citations

17.

Yu, Xiang‐Nan, et al.. (2018). Efficacy of Nucleoside Analogs for Chronic Hepatitis B Virus-Related Hepatocellular Carcinoma After Curative Treatment: A Meta-Analysis. Digestive Diseases and Sciences. 63(12). 3207–3219. 13 indexed citations

18.

Jiang, Xuemei, Jinsheng Wu, Yingai Zhang, et al.. (2018). MiR-613 functions as tumor suppressor in hepatocellular carcinoma by targeting YWHAZ. Gene. 659. 168–174. 23 indexed citations

19.

Wu, Jinsheng, et al.. (2016). Effect of saracatinib on pulmonary metastases from hepatocellular carcinoma. Oncology Reports. 36(3). 1483–1490. 8 indexed citations

20.

Jiang, Xuemei, Xiang‐Nan Yu, Hairong Zhu, et al.. (2016). Prognostic significance of eukaryotic initiation factor 4E in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology. 142(11). 2309–2317. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact